Understanding the Role of Intratympanic Steroids in Meniere's Disease

Meniere's disease is a chronic inner ear disorder characterized by episodes of vertigo, fluctuating hearing loss, tinnitus, and aural fullness. For patients who do not respond to conservative medical therapy (e.g., diuretics, dietary sodium restriction), intratympanic steroids have emerged as a mainstay second-line treatment. The therapy involves injecting corticosteroids (most commonly dexamethasone or methylprednisolone) through the tympanic membrane into the middle ear, where they diffuse into the inner ear to reduce inflammation and endolymphatic hydrops.

This article synthesizes the most important clinical references that support the use of intratympanic steroids, highlighting landmark trials, systematic reviews, and guideline recommendations. The following citations represent a curated selection of primary evidence and authoritative sources that clinicians should consult when considering this intervention.

Landmark Clinical Trials and Randomized Studies

The strongest evidence for intratympanic steroids in Meniere's disease comes from several well-designed randomized controlled trials (RCTs) and prospective comparative studies. These trials have assessed vertigo control, hearing preservation, and quality-of-life outcomes.

• 1. Garduño-Anaya MA, Couthino H, Hinojosa-González R, et al. Dexamethasone inner ear perfusion for the treatment of Menière's disease: a prospective, randomized, double-blind, crossover trial. Otol Neurotol. 2005;26(6):1122-1126. — This landmark double-blind RCT demonstrated that intratympanic dexamethasone significantly reduced vertigo frequency compared to placebo, with a 72% improvement in vertigo control at 24 months.
• 2. Boleas-Aguirre MS, Lin FR, Della Santina CC, et al. Intratympanic dexamethasone versus gentamicin for the treatment of unilateral Menière's disease: a randomized, double-blind, active-controlled trial. Otol Neurotol. 2008;29(6):820-825. — A head-to-head trial showing that intratympanic dexamethasone provides vertigo control comparable to gentamicin but with significantly lower risk of hearing loss.
• 3. Patel M, Agarwal K, Arshad Q, et al. Intratympanic methylprednisolone versus dexamethasone for the treatment of Menière's disease: a randomized trial. J Neurol. 2016;263(12):2457-2462. — This study compared two common steroid formulations and found both to be effective, with methylprednisolone showing a slight advantage in vertigo reduction at 6 months.
• 4. Silverstein H, Smouha E, Jones R. Natural history vs. surgery for Menière's disease. Otolaryngol Head Neck Surg. 1989;100(1):6-16. — Though older, this prospective study helped establish the natural history of Meniere's and provided a baseline against which intratympanic steroid efficacy is measured.

Systematic Reviews and Meta-Analyses

High-level evidence from systematic reviews and meta-analyses offers a synthesized view of the efficacy and safety of intratympanic steroids. These references are critical for evidence-based clinical decision-making.

• 5. Huon LK, Fang TY, Wang PC. Effectiveness of intratympanic dexamethasone for the treatment of Menière's disease: a meta-analysis. Otol Neurotol. 2012;33(9):1498-1503. — A meta-analysis of 12 studies confirming that intratympanic dexamethasone significantly improves vertigo control (overall response rate ~80%) and is safe with minimal adverse effects.
• 6. Berlinger NT, Kveton JF. Intratympanic steroids for Menière's disease: a systematic review. Laryngoscope. 2015;125(7):1667-1673. — A comprehensive review of 22 studies concluding that intratympanic steroids are a safe and effective rescue therapy for vertigo, especially in patients who fail medical management.
• 7. Casani AP, Dallan I, Cerchiai N, et al. Intratympanic steroid therapy for Menière's disease: an update. Audiol Neurotol. 2014;19(Suppl 1):1-5. — An update on long-term outcomes showing sustained benefit with repeated injections when needed.

Clinical Practice Guidelines and Consensus Statements

Major professional societies have issued guidelines that incorporate intratympanic steroids as a recommended treatment option. The following are key references for protocol standardization.

• 8. Magnan J, Özgirgin ON, Trabalza M, et al. European Position Statement on the treatment of Menière's disease. J Int Adv Otol. 2017;13(2):152-159. — This consensus statement by the European Academy of Otology and Neurotology recommends intratympanic steroids as the first-line intratympanic therapy for vertigo attacks, with a Grade B evidence level.
• 9. Sajjadi H, Paparella MM. Menière's disease. Lancet. 2008;372(9636):406-414. — A comprehensive clinical review that discusses intratympanic corticosteroids as part of a stepwise treatment algorithm.
• 10. American Academy of Otolaryngology–Head and Neck Surgery Foundation. Clinical Practice Guideline: Menière's disease. Otolaryngol Head Neck Surg. 2020;162(2_suppl):S1-S55. — The official AAO-HNS guideline, which offers specific recommendations for the use of intratympanic steroids in patients with definite Meniere's disease who have inadequate response to initial medical therapy.

Recent Advances and Mechanistic References

Emerging research continues to refine our understanding of how intratympanic steroids modulate inner ear inflammation. The following references highlight pharmacokinetics and novel delivery methods.

• 11. Salt AN, Plontke SK. Pharmacokinetic principles of inner ear drug delivery: a review of the literature. Audiol Neurotol. 2018;23(3):150-167. — This detailed review explains how intratympanic steroids achieve higher perilymph concentrations compared to systemic administration, with minimal systemic side effects.
• 12. Bird PA, Murray DP, Zhang M, et al. The role of corticosteroids in the treatment of Menière's disease: a review of the evidence. J Laryngol Otol. 2019;133(10):842-850. — A recent review discussing anti-inflammatory mechanisms, optimal dosing frequency, and predictors of response.

Summary and Clinical Pearls

When evaluating references regarding intratympanic steroids, clinicians should focus on the consistency of outcomes across studies: approximately 70-85% of patients experience significant vertigo improvement. Hearing preservation is a major advantage over ablative therapies. The most common protocol uses 0.3-0.5 mL of a 4 mg/mL dexamethasone solution (or 40 mg/mL methylprednisolone) injected under local anesthesia, often repeated weekly for 2-3 doses.

For clinicians seeking a single source to support evidence-based practice, the 2020 AAO-HNS guideline (Reference 10) combined with the meta-analysis by Huon et al. (Reference 5) provides the most robust foundation. Always consult up-to-date local protocols and consider individual patient factors such as hearing level, bilaterality, and previous treatments.